Novo Nordisk's single-molecule GLP-1 and amylin agonist, now named zenagamtide, tested as a weekly shot and a daily pill. In phase 3, not approved.
Also called zenagamtide, NNC0487-0111, oral amycretin, subcutaneous amycretin, AMAZE trials
When Amycretin's status or evidence changes, it's in the next morning's email.
Amycretin is one peptide that switches on both the GLP-1 receptor (the target of semaglutide) and the amylin and calcitonin receptors (the targets of cagrilintide). CagriSema reaches the same receptors with two separate drugs; amycretin does it with one. In 2026 it received the official name zenagamtide. Novo Nordisk is testing it as a weekly injection and as a daily tablet.
The early numbers are large but come from small trials. In a phase 1b/2a study of 125 adults with overweight or obesity, weekly injections gave 22.0% weight loss at 36 weeks on 20 mg and 24.3% on 60 mg, against placebo results that ranged from 1.1% loss to 2.3% gain. Novo Nordisk reported 13.1% weight loss in 12 weeks at the highest dose of the daily tablet. In a 36-week phase 2 trial of 448 adults with type 2 diabetes, the company reported that the injection gave up to 14.5% weight loss and the tablet up to 10.1%.
Amycretin is not approved anywhere as of October 2026. The phase 3 AMAZE program in obesity started in February 2026, with trials against semaglutide and in sleep apnea, knee arthritis and heart failure, and AMBITION trials in type 2 diabetes began in August 2026. Most of these trials finish in 2028 or later.
What it binds to, and what happens inside the body after that, step by step.
Amycretin activates the GLP-1 receptor and the amylin and calcitonin receptors with one molecule. GLP-1 signaling cuts appetite and raises insulin when blood sugar is high. Amylin signaling in the brainstem makes meals end sooner and slows stomach emptying. Combining the two pathways is the same idea as CagriSema, packed into one drug.
Human results and animal results are kept apart below. A result in rats tells you a mechanism is plausible. It does not tell you what happens in a person.
Randomized placebo-controlled trials in people with obesity and in type 2 diabetes show large weight loss and lower HbA1c, but they are early-phase and small: the obesity data come from 125 and 144 people at one US site, with many dropouts. No phase 3 trial has reported, and there is no head-to-head result against semaglutide or tirzepatide yet.
125 adults with overweight or obesity, single US site
Weight change was -22.0% on 20 mg and -24.3% on 60 mg at 36 weeks, -16.2% on 5 mg at 28 weeks, and -9.7% on 1.25 mg at 20 weeks, vs -1.1% to +2.3% on placebo.
Read the study262 adults with type 2 diabetes on metformin, 36 weeks
HbA1c fell from 0.9 points (0.4 mg) to 1.7 points (40 mg); Novo reported weight loss of up to 14.5% vs 2.6% on placebo.
Read the study186 adults with type 2 diabetes on metformin, 36 weeks
HbA1c fell 0.9 to 1.4 points on 6 to 50 mg; GI side effects rose with dose, from 26% to 47%, vs 23% on placebo.
Read the study144 adults with overweight or obesity, single US site
Side effects were all mild or moderate, mostly GI; Novo reported 13.1% weight loss at 12 weeks on 2 x 50 mg vs 1.2% on placebo.
Read the study448 adults with type 2 diabetes, injection and tablet arms
Weight loss up to 14.5% with weekly injections and 10.1% with the daily tablet at 36 weeks, with no plateau at the higher doses.
Read the studyNo preclinical studies are listed as key studies here. The human data above carries the evidence.
When a new Amycretin study in people is published, the daily email covers it.
These are questions the published research has not answered.
No product containing Amycretin is approved as a medicine by the FDA.
Phase 3. The AMAZE obesity program started with AMAZE 1 (1,150 adults, 84 weeks) in February 2026; other AMAZE trials test it against semaglutide in type 2 diabetes, in sleep apnea, in knee osteoarthritis and as a tablet. A heart failure outcomes trial (about 5,610 people) started in May 2026, and the AMBITION 7 diabetes trial in August 2026. No marketing application has been filed. WADA: not named on the 2026 Prohibited List, but with no approval anywhere it falls under S0 (non-approved substances), prohibited at all times. This is our reading of the S0 rule, not a WADA ruling on amycretin by name.
When the FDA or WADA changes Amycretin's status, it's in the next morning's email.
No human half-life has been published for Amycretin, so we do not draw a clearance curve. Half-lives quoted online for it are usually estimates from animal data.
This table records the doses that trials and approved labels used, with the source for each row. It is a record of research, not a recommendation, and it is open to free members.
Which symptoms are expected and which mean stop and get help: side effects and red flags.
Tap a claim to see what the studies found.
That was the 60 mg arm of a 125-person phase 1b/2a study at one site, estimated as if everyone stayed on treatment. Phase 3 trials with thousands of people have not reported yet.
Both target GLP-1 and amylin receptors, but CagriSema is two separate drugs (cagrilintide plus semaglutide) and amycretin is one molecule. They have not been compared in a trial.
In the phase 2 diabetes trial, the tablet gave up to 10.1% weight loss vs up to 14.5% for the weekly shot over 36 weeks, and the tablet needs far higher doses.
Only Novo Nordisk makes the clinical product, and its full structure is not public. Online vials have no verified identity, purity or dose.
No approved product exists. Trial supplies are handled under the sponsor's protocol, which is not public.
No public label or stability data.
One email when a trial reads out, a label changes or the FDA acts on a peptide. Free, every source linked, unsubscribe any time.